Table 1.
Patient Selection Criteria
| Selection criteria | Patients using sulfonylurea, N (%) | Patients using SGLT-2 inhibitor, N (%) |
|---|---|---|
| Patients with ≥1 pharmacy claims for an SGLT-2 inhibitor or a sulfonylurea (including fixed-dose combinations) between January 1, 2015, and December 31, 2015 (earliest claim = index date; class of earliest medication = index class)a | 470,284 (100.0) | 151,514 (100.0) |
| Age ≥18 years at index date | 470,157 (100.0) | 151,469 (100.0) |
| Continuous enrollment in medical and pharmacy benefits for ≥12 months before the index date (baseline period) | 371,836 (79.1) | 124,367 (82.1) |
| Continuous enrollment in medical and pharmacy benefits for ≥6 months after the index date (follow-up period) | 302,246 (64.3) | 87,040 (57.4) |
| ≥1 nondiagnostic medical claimsb with a diagnosis code for type 2 diabetes in any position during the baseline period | 280,717 (59.7) | 82,542 (54.5) |
| No medical claims with a diagnosis code for type 1 diabetes during the baseline or follow-up periods | 255,498 (54.3) | 72,846 (48.1) |
| No medical claims with a diagnosis code for gestational diabetes during the baseline or follow-up periods | 255,216 (54.3) | 72,808 (48.1) |
| No medical claims with a diagnosis code for any pregnancy condition during the baseline or follow-up periods | 253,453 (53.9) | 72,092 (47.6) |
| No use of the index medication class during the baseline period | 27,314 (5.8) | 29,228 (19.3) |
| No use of the comparator medication class during the baseline period or on the index date | 25,490 (5.4) | 17,724 (11.7) |
| Final unmatched population | 25,490 (5.4) | 17,724 (11.7) |
a
Patients with more than 1 type of SGLT-2 inhibitor or sulfonylurea on the index date were excluded from the study.
b
Claims that are not associated with a diagnostic workup used to rule out the presence of a condition, such as claims for laboratory tests.
SGLT-2 indicates sodium-glucose cotransporter 2.